Anti-CD73 antibody [IHC073] (STJA0042128)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG1k
General Information
| Short Description | Mouse monoclonal anti-CD73 for use in IHC-p in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-p |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | IHC073 |
| Isotype | IgG1k |
| Conjugation | Unconjugated |
| Formulation | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Storage Instruction | Store at 2-8°C for up to 1 year. Do not freeze. |
Target Information
| Specificity | Tested and validated on placenta, tonsil, hepatocellular carcinoma tissue. |
Additional Info
| Background | Cluster of Differentiation 73 (CD73) , also known as Ecto-5 NA-Nucleotidase (ecto-5 NA-NT) , is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells in vitro, as well as tumour angiogenesis and tumour immune escape in vivo. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma. |
Information sourced from Uniprot.org